Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 1 What is the same? What is reduced/removed? What is added/expanded? INTERMACS.

Slides:



Advertisements
Similar presentations
Overview of the Study Protocol
Advertisements

Tips to a Successful Monitoring Visit
The Execution and Management of a Complex Clinical Trial Elizabeth K. Walsh, RN ECTSS 2013 Conflicts of Interest Advisory Board for TAVR Administrators.
Research and Development Department A Quick Guide to Using EDGE v2 for Researchers Version 1.2 – 23 February
Provincial Hospital Resource System How to update Resource Boards in the PHRS.
Upcoming TIEDI ® OMB Changes Q&A Session Implementation date: March 31, 2015.
Medication Reconciliation
Jennifer Cohen, MD, Heather Costa, PhD, Robert Russo, MD, PhD, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA The MagnaSafe Registry:
Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.
Estimating Benefit in Ambulatory Heart Failure Patients MedaMACS Progress Report 2014 Garrick C. Stewart, MD Brigham and Women’s Hospital.
Case Report Form Start-up Meeting March 25, 2010 Kingston, ON.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Sixth Annual Meeting Coordinator Training Session March 11, :00pm to 9:00pm Arlington, VA 1 INTERMACS Coordinator Training March 2012.
Pediatric Research in Office Settings (PROS). Introduction  Four million births each year in U.S.  Decreasing lengths of postpartum stay  Responsibility.
Coordinator Training Session, March 11,  Robert Kormos, MD INTERMACS Co-Principal Investigator GO TO PAGE 58 in the SITE USERS’ GUIDE INTERMACS.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Consent Training Module Version 4: August 7th, 2013.
Interagency Registry for Mechanically Assisted Circulatory Support Marissa A. Miller, DVM, MPH National Heart, Lung, & Blood Institute.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
New Adverse Event Reporting Policy Effective September 1, 2007.
... for our health Wisconsin Research and Education Network and the University of Wisconsin Department of Family Medicine Collaboration Among Pharmacists.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Deciphering the Continuing Review Form Research Compliance Administration Training Presentation Wednesday, August 15, 2007 Presenter:Heather Kemp, MBA.
Entering Training & Member Development Hours in the My Service Log System A Step-by-Step Overview 1.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.
BOLD 2.0 Navigation Help Guide Note: BOLD will be inaccessible from 9:00 pm ET on Friday, June 1, to 7:00 am ET on Monday, June 4, so that the upgrade.
Registry Data Collection in Pediatric VADs: Challenges and Opportunities INTERMACS Eighth Annual Meeting May 5, 2014 David Rosenthal, MD Stanford Children’s.
Module 3: Informed Consent. This training session contains information regarding: Documenting consent Documenting consent Conducting informed consent.
Consent for Research Study A study for patients diagnosed with locally advanced breast cancer Learning if the imaging agent, [ 18 F] fluorothymidine (FLT),
Welcome To INSPIR Training Please be sure Please be sure to sign- in to sign- in Please be sure you try to log – on to INSPIR before you leave Please be.
CBMTG 0801 Moving Forward …. Activation Timeline.
INTERMACS: June 2006 – December 2012: CMS Report Adults: n=7849 All primary implants as of 12/31/2012 n= 7928 Pediatric patients: n=79 (patients < 19 yrs.
Investigator’s Meeting
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
Mette Krag, MD, coordinating investigator
Module 4: Central Randomization System (CRS). This training session contains information regarding: Overview of Data Collection & Entry Overview of Data.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
Sponsor Visits and Monitoring
Patient Portal Website Patient Training Powered by the.
Medidata Rave Start-Up Information
1 Data Quality Report Quality Assurance Report Live Data Download Site Datasets (SAS) Research Datasets Customized Cohort Reports Outcome Analytics Patient.
Agents Intervening against Delirium in Intensive Care Unit (AID-ICU): An international inception cohort study AID-ICU Primary investigator: Marie Oxenboell-Collet.
1 Intermacs 10 th Annual Meeting and Scientific Sessions Intermacs: Products for the Sites Friday, March 11, 2016: 7:00-8:30pm Omni Hotel, Grand Ballroom.
How to complete and submit a Final Report through Mobility Tool+ Technical guidelines Authentication, Completion and Submission 1 Antonia Gogaki IT Officer.
Session I: Web Based Reporting: What You Can Get From the Database Data Quality Report Quality Assurance Report I. Accessing Your Data Examining/Validating.
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
How to complete and submit a Final Report through
The Role and Responsibilities of the Clinical Research Coordinator
Søren Marker Jensen, MD, coordinating investigator
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Ryan Cantor, MSPH Director of Statistical Reporting, Intermacs
10th Annual Meeting: Friday, March 11th – Products for the Sites
MAINTAINING THE INVESTIGATOR’S SITE FILE
Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,
Clinicaltrials.gov Update
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
Cardiac Cath NUR 422.
STS Intermacs and Pedimacs
Stakeholder Monthly Webinar
Interagency Registry for Mechanically Assisted Circulatory Support Web-Based Reporting What can you get from the Database? Friday March 3, 2017.
ARCADIA Coordinator Webinar
Annual Spring Meeting April 26, 2016
Consent Training Module
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Impact of Marital Status on LVAD Mortality: A Single Center Experience Linda Njoroge MD, Mohamed Khayata MD, Kevin Charnas, Paul Bate, Madison Edge, James.
E-CRF Overview Oracle® Clinical Remote Data Capture Training (Version 4.6 HTML) e-CRF Completion John McDonach Manager CDM, PPD.
Module 4: Central Randomization System (CRS)
Presentation transcript:

Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 1 What is the same? What is reduced/removed? What is added/expanded? INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 2 What is the same?  No changes in AE definitions (RHF levels added)  Structure remains the same:  FORMS: screening, demographic, pre-implant, follow-up, rehospitalization, discharge, etc.  Follow-up schedule remains the same:  1 week, 1 month, 3 month, 6 month and every 6 months thereafter INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 3 What is reduced/removed?  Streamlining of Adverse Event data entry by:  Removal of all AE reminders from: – Follow-up Forms – Implant Discharge Form – Rehospitalization Form  Providing a single data entry ‘place’ for adverse events – Look for this button at the top of the ‘patient overview screen’  Reduction of the implant discharge form  Comorbidities in Pre-Implant form more streamlined and well defined and merged with the contraindications for transplant INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 4 What is added/expanded?  We are using a ‘trigger’ process for some Adverse Events:  (Right heart failure, hemolysis, hepatic dysfunction, hypertension, renal dysfunction)  Still allows the Site to make the final decision on these adverse events  Patient transfer implemented  Device Malfunction and Device Parameters based on specific device (schematics) – easier to enter for a particular device  KCCQ – Kansas City Cardiomyopathy Questionnaire  Functional Capacity expanded  Gait speed INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Overview of Data EntryNaftel 5  This is to current members AND new members  Patient Eligibility  Prospective Design  Major End Points  Observational Study Monitoring Board (OSMB)  Site Enrollment  Data Entry  Training (form by form) paying special attention to the major changes INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Overview of Data EntryNaftel 6  This is to current members AND new members  Patient Eligibility –FDA approved durable devices –Informed Consent –No Exclusions Except Incarcerated Persons INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Overview of Data EntryNaftel 7  This is to current members AND new members  Major End Points –Death while a device is in place –Transplantation (connect to the OPTN Database) –Recovery (death and transplant for 1 year) –Device Exchange –Follow-up and Censoring INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Overview of Data EntryNaftel 8  This is to current members AND new members  Patient Eligibility  Prospective Design  Major End Points  Observational Study Monitoring Board (OSMB)  Site Enrollment  Data Entry  Training (form by form) paying special attention to the major changes INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 WHY? Naftel 9  Why are you participating in INTERMACS?  How are we monitoring data quality? INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Overview of Data EntryNaftel 10 INTERMACS Coordinator Training March 2012

Coordinator Training Session: March 11, 2012 Training for the Data Entry System 11 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11,  Gail Mertz, RN INTERMACS Nurse Monitor GO TO PAGE 10 in the SITE USERS’ GUIDE INTERMACS Coordinator Training March 2012

Coordinator Training Session, March11,  Screening Log –Included patients –Excluded patients Goal: To capture all MCSD patients at each institution  Screening Log –Included patients –Excluded patients Goal: To capture all MCSD patients at each institution INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, Added: Domestic Partner option for Marital Status  Page 13 New Version INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11,  Lynne Stevenson, MD INTERMACS Co-Principal Investigator GO TO PAGE 14 in the SITE USERS’ GUIDE INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, Transplant Concerns/Contraindications  Page 15 New Version INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, Implant Decision Date: REMOVED IV Inotrope Implant:  Changed to within 48 hours of implant  Page 20 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, Swan Hemodynamics:  Added Heart rate  Added cardiac index/CI  Page 23 & 24 Medications:  Added Loop Diuretics  Added Phospodiesterase inhibitors  Page 25 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, Minute Walk:  Added Gait Speed  Page 27 QOL:  Added KCCQ  Page 28 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11,  Robert Kormos, MD INTERMACS Co-Principal Investigator GO TO PAGE 29 in the SITE USERS’ GUIDE INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, Added: Associated Surgical Findings  page 30 Time in OR: REMOVED INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, Associated Surgical Findings  page 30 New Version INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11,  Gail Mertz, RN INTERMACS Nurse Monitor GO TO PAGE 31 in the SITE USERS’ GUIDE INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11,  Doppler Opening Pressure  AE Triggers  Page 23 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11,  1 week visit window is now: +/- 3 Days!  Page 31 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11,  Patient Location Options  Page 31 New Version INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, 2012 FOLLOW UP VISITS AND DATA ENTRY GUIDELINES  The windows for visits are not the same as the guidelines for form completion.  The web-based data entry (WBDE) system is prospective and the forms should be filled out as the implant, follow-up dates, and events occur.  Forms should generally be completed within seven (7) days of an event, but always within 30 days. Follow Up Visit Acceptable Time Window for Visit 1 week  3 Days (4 – 10 days post implant) 1 month  7 Days (23 – 37 days post implant) 3 month  1 Month (2 – 4 months post implant) 6 months and beyond  2 Months (4 – 8 months post implant, etc.) 28 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, Implant Discharge Date/Status at Discharge  Page 48 To Add an event use the ICON the top of the overview screen: New Version INTERMACS Coordinator Training March 2012

REHOSPITALIZATION 30  Page  Discharge Date  Primary Reasons for Rehospitalizations additions: Syncope without known cause, Fever of unknown cause, Diagnostic procedure, Planned medical management  Rehospitalization Intervention: Transplantation Coordinator Training Session, March 11, 2012 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, 2012 Patient Transfers Sending Institution  Ensure All Forms and Visits Have Been Completed  Complete Patient Registry Status Form Receiving Institution  Patient must agree to continued participation in INTERMACS at the new institution  Receiving institution must have IRB approval for Amendment 1 Version 2.3 Dated: 9/15/2010  Obtain “Authorization to Release Information Consent” at the receiving institution.  Obtain INTERMACS Registry Consent Form at receiving institution.  Please forward copies of both consents to Mary Lynne Clark at the INTERMACS DCC 29 INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11, To be completed by the sending institution, after all the patients forms and visits have been completed. The Receiving hospital will have ‘read only’ access to the pre- transfer records.  Page 55 To access Patient Registry Status Form New Version INTERMACS Coordinator Training March 2012

Coordinator Training Session, March 11,  Page 56  Device malfunction  Infection  Device Thrombosis Expanded Options New Version

Coordinator Training Session, March 11,  Page 57 Added primary causes of death:  MSOF  Withdrawal of support INTERMACS Coordinator Training March 2012